Anti-VEGF treatment strategies on three subtypes of neovascular age-related macular degeneration in real-world clinical setting: A multicenter cohort study in Japan.

This real-world clinical study demonstrates that treatment regimens were similar in three subtypes and aflibercept was used in 70% of all patients. Approximately 5 injections were given in the first year regardless of the anti-VEGF agent, which was significantly less in PRN regimen than in TAE. VA improvement was yielded after 1-year anti-VEGF therapy in all three subtypes, but was not significant in RAP.